However, its clinical significance and function in leukemogenesis is still unclear. In the present study, we detected EDAG mRNA expression in a panel of leukemia cell lines and the bone marrow mononuclear cells (BMMC) of 75 acute myeloid leukemia (AML) patients to explore the clinical significance of EDAG. Then we investigated the effect of EDAG gene knockdown by RNA interference (RNAi) on leukemia cell line K562 to study the molecular mechanism.
High expression of EDAG and its significance in AML
1 Downregulation of EDAG expression also occurs during erythroid differentiation of K562 cells. Overexpression of EDAG in NIH3T3 cells causes cell transforming and tumor forming in nude mice. 2 Furthermore, EDAG gene maps to chromosome 9q22, which contains a cluster of leukemic breakpoints and genes important for leukemogenesis. 1 However, its clinical significance and function in leukemogenesis is still unclear. In the present study, we detected EDAG mRNA expression in a panel of leukemia cell lines and the bone marrow mononuclear cells (BMMC) of 75 acute myeloid leukemia (AML) patients to explore the clinical significance of EDAG. Then we investigated the effect of EDAG gene knockdown by RNA interference (RNAi) on leukemia cell line K562 to study the molecular mechanism.
The expression of EDAG mRNA in the leukemia cell lines and other samples were detected by semiquantitative RT-PCR. The PCR conditions and the numbers of cycles were chosen according to preliminary experiments in which the amount of product was directly proportional to the quantity of starting cDNA. In summary, total cellular RNA was extracted with the use of Trizol Reagent (Invitrogen). mRNA from 1 mg of total cellular RNA was reverse transcribed using an M-MLV reverse transcriptase commercial kit (Invitrogen). cDNA (2 ml) was amplified by PCR at 941C for 30 s, X1C for 30 s, 721C for 60 s with 30 cycles. X refers to the annealing temperature ( Table 1) . The results showed that a high level of EDAG transcripts was detected in K562, KG-1a, Jurkat, Namalva and cord blood CD34 þ cells. A low level of expression was found in Raji, EBV transformed lymphoblastoid cell line LCL-H, hepatoma cell line SMMC-7721, U937 and normal adult bone marrow. However, no expression was detected in HL-60, NB4, J6-1 (derived from a myelomonocytic leukemia patient in 1976) 3 cells. The different expression patterns of EDAG in various leukemia cell lines suggest that EDAG mRNA levels may vary in different leukemia patients. In this study, we also analyzed EDAG mRNA expression in the bone marrow of 75 AML patients (65 with de novo AML and 10 with complete remission (CR) at the time of sample collection) and 15 normal donors. The patients' clinical characteristics are summarized in Table 2 . The diagnosis was based on FAB by standard morphological, cytochemical and immunophenotypic criteria. For statistical analysis, Wilcoxon rank-sum test (Mann-Whitney U test) was used for two-group means comparison; Kruskal-Wallis test (ANOVA) was used for more than two means comparison. EDAG mRNA was expressed in BMMC of all cases detected. In de novo AML patients, its relative expression averaged 0.6470.28, which was significantly higher than that in the normal donors (0.3570.11). We did not detect a marked difference between the CR AML patients (0.3870.16) and the normal donors. We further investigated whether EDAG expression related to the leukemia patients' clinical characteristics. No significant differences were found when the patients were divided into different groups regarding age, sex, initial WBC count, FAB subtype and CD34 expression ( Table 2 ). Of the 65 de novo AML patients, 53 received therapy in our hospital. A total of 35 patients achieved CR within two courses of standard induction therapies. Interestingly, we found that EDAG mRNA expression in these patients (detected before therapy) was significantly lower than that in patients with no remission (NR) (0.6270.23 vs 0.9170.11, P ¼ 0.029). Moreover, patients with overall response to the therapy (CR þ PR) also had significantly lower value than patients with NR (0.6470.22 vs 0.9170.11, P ¼ 0.023). The typical experiments are shown in Figure 1b . Our results suggest that initial EDAG gene expression level might be associated with therapy response.
Since EDAG expression is high in CD34 þ cells, we wonder whether the percentage of CD34 þ cells would affect the level of EDAG expression in the AML patients detected. We compared EDAG mRNA expression in CD34
þ AML patients and CD34
À AML patients. The sample was defined as CD34 þ , when greater than 10% blasts were positively stained. 3 Interestingly, we found that no significant difference was found in these two groups (0.6570.25 vs 0.6270.24, P40.05). Moreover, there was no correlation between CD34 and EDAG expression. We also separated CD34 þ and CD34 À cells from two AML patients and we found that EDAG expression could also be detected in CD34
À cells of these patients (Figure 1a) . So we think a high expression of EDAG in AML may correlate with the pathological processes, while not just the differentiation status of AML cells.
To explore the role of EDAG in leukemia cells, we studied the effect of knockdown of EDAG expression by RNAi in K562 cells. Two siRNA fragments (ED1 and ED2, Table 1 ) aiming at EDAG were designed and synthesized, then were inserted into the siRNA expression vector pSilencer 3.0-H1 by HindIII and BamHI ligation, which were designated as pED1 and pED2, respectively. Purified recombinant plasmids and negative control plasmid (a circular plasmid pSilencer 3.0-H1 encoding Table 1 Primers used for RT-PCR analysis of gene expression a hairpin siRNA with limited homology to any known sequences in the human, mouse, and rat genomes) were transduced into K562 cells using LF2000 according to the manufacturer's protocols, respectively. Semiquantitative RT-PCR analysis showed that the expression level of EDAG mRNA was reduced to 68% (pED1) and 40% (pED2) of the negative control after 48 h, respectively. Cell number of K562 cells transduced with pED1 (T1) and pED2 (T2) increased from 1 Â 10 4 to 2.4 Â 10 4 and 2.5 Â 10 4 after 48 h, respectively, whereas it reached 3.5 Â 10 4 and 3.6 Â 10 4 in K562 cells transduced with negative control vector (B) or parental K562 cells (N), respectively. The cell number of test group (T1 and T2) was significantly lower than that of control group (B and N) (Po0.05). In addition, expression of cell surface marker including glycophorin A and CD117 were examined by flow cytometry on 0 and 48 h. Positive rates of cells with glycophorin A in different groups were 78.17% (T1), 81.1% (T2) and 77.47% (N), whereas 62.27% at the 0 h. No statistical difference was found between them. However, the fluorescence intensity of cell surface glycophorin A in T1 (131.88) and T2 (173.46) group were higher than that in B group (100.52, Po0.05) and K562 cells on 0 h (50.70, Po0.01). CD117 was not detected on the surface of K562 cells. It seems that transfection with a negative control plasmid (the B group) also had a certain effect on the differentiation of K562 cells, but the effect was significantly weaker than that in the T1 and T2 groups. Our results suggest that inhibition of EDAG gene expression could inhibit the growth and promote the differentiation of K562 cells. This accords with the reports of others. 2 In this study, we also studied the effect of knockdown of EDAG expression by RNAi on the expression of some genes related to cell cycle, apoptosis or hematopoiesis, including cyclin A1, cyclin D1, cyclin D2, cyclin E, cdk2, p21, SCL/tal-1, GATA-2, c-myb, c-Myc, Bcl-2, NF-kB, and Notch1 (Figure 2) . We found that p21 expression was increased in the EDAG knockdown K562 cells. As the cyclin-dependent kinase inhibitor, p21 is a proliferation inhibitor. Yang et al 4 reported that the gene transfection of p21 inhibited proliferation of K562 cells. We postulated that downregulation of EDAG might inhibit the proliferation of K562 cells by inducing the expression of p21. We also found that the expression of c-myb was significantly reduced in the EDAG knockdown K562 cells. C-myb is a transcriptional factor and its target genes include CD34, c-kit, mim-1, CD4, c-myb, c-myc, cdc-2, CD4, lysosome, etc. Many of them are specific for the hematopoietic compartment, and others are related to the cell cycle and/or apoptosis. For some target genes, cooperation of myb with other proteins is crucial for manifestation of full transactivating ability. 5 It is overexpressed in some of leukemia such as AML, ALL and CML. C-myb antisense oligodeoxynucleotides could inhibit the in vitro proliferation of chronic myelogenous leukemia progenitor cells. 6 Our results suggest that EDAG might be a new regulator of c-myb expression. However, the precise mechanism needs further investigation. Bcl-2 mRNA expression was low in parental K562 cells and K562 cells transfected with the negative control plasmid, and it could not be detected in the EDAG knockdown K562 cells. Li et al 2 reported that EDAG could increase the protein expression of c-myc, Bcl-2 and Bcl-xL and enhance the transcriptional activity of NF-kB. However, we did not detect significant differences in c-myc and NF-kB mRNA expression in the EDAG knockdown K562 cells. The discrepancy may be due to different model and methods used. Interestingly, our study seems to reflect an inverse relationship between EDAG expression and the therapy response. The mechanism of chemo resistance to AML includes P-gp/MDR1 mechanisms and non-P-gp mechanisms such as altered apoptotic response and the capacity of autonomous proliferation. 7 We also analyzed EDAG mRNA expression in the k562/A02 cells (K562 cells with multidrug resistance). No significant differences were found between the K562/A02 cells and the control K562 cells. Since several evidences showed that EDAG might promote the proliferation and resist the apoptosis of leukemia cells, we postulate that EDAG may influence the therapy response of AML patients mainly through the non-P-gp mechanisms. Moreover, high expression of c-myb or Bcl-2 protein in AML cells is also associated with poor response to chemotherapy. 7, 8 Whether these correlate with the effects of EDAG observed in our study needs further investigation.
In summary, our data suggest a modulator role for EDAG in AML and EDAG might be a new target in the treatment of AML. Effects of EDAG knockdown on gene expressions. The expression of some hematopoiesis associated genes and apoptosis or cell cycle related genes including SCL/tal-1, GATA-2, c-myb, Notch1, cyclin A1, cyclin D1, cyclin D2, cyclin E, cdk2, p21, Bcl-2, c-myc and NF-kB were detected using semiquantitative RT-PCR analysis. The gel prints are representative of results from three independent experiments. Expression of Notch1, cyclin A and cyclin D1 could not be detected in the K562 cells of each group. N: parental K562 cells; B: K562 cells transfected with negative control vector; T1: K562 cells transfected with pED1; T2: K562 cells transfected with pED2.
